MSA
LGND icon

Mason Street Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Mason Street Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,767
Closed -$854K – 678
2020
Q4 		$854K Sell
13,767
-27
-0.2% -$1.54K 0.01% 1000
2020
Q3 		$820K Sell
13,794
-304
-2% -$20.7K 0.02% 903
2020
Q2 		$984K Buy
14,098
+25
+0.2% +$1.58K 0.02% 825
2020
Q1 		$638K Sell
14,073
-902
-6% -$51.1K 0.01% 899
2019
Q4 		$974K Sell
14,975
-1,007
-6% -$67.3K 0.02% 894
2019
Q3 		$992K Sell
15,982
-763
-5% -$47.9K 0.02% 854
2019
Q2 		$1.19M Sell
16,745
-683
-4% -$50.3K 0.02% 789
2019
Q1 		$1.37M Sell
17,428
-418
-2% -$31.7K 0.03% 768
2018
Q4 		$1.51M Buy
17,846
+7,822
+78% +$834K 0.04% 624
2018
Q3 		$1.72M Buy
10,024
+154
+2% +$23.2K 0.04% 657
2018
Q2 		$1.28M Buy
9,870
+484
+5% +$54K 0.03% 786
2018
Q1 		$967K Buy
9,386
+587
+7% +$58.1K 0.02% 849
2017
Q4 		$752K Buy
8,799
+306
+4% +$26.5K 0.02% 920
2017
Q3 		$721K Buy
8,493
+967
+13% +$76.6K 0.02% 922
2017
Q2 		$570K Buy
7,526
+412
+6% +$28.8K 0.01% 965
2017
Q1 		$470K Buy
7,114
+452
+7% +$29.7K 0.01% 1005
2016
Q4 		$422K Buy
6,662
+399
+6% +$25.2K 0.01% 1012
2016
Q3 		$399K Buy
6,263
+325
+5% +$23.9K 0.01% 997
2016
Q2 		$442K Buy
5,938
+772
+15% +$57.3K 0.01% 938
2016
Q1 		$345K Buy
5,166
+480
+10% +$29.2K 0.01% 974
2015
Q4 		$317K Buy
4,686
+419
+10% +$25.9K 0.01% 967
2015
Q3 		$228K Buy
4,267
+304
+8% +$18.4K 0.01% 1036
2015
Q2 		$249K Buy
3,963
+170
+4% +$9.28K 0.01% 1017
2015
Q1 		$182K Buy
3,793
+36
+1% +$1.38K 0.01% 1114
2014
Q4 		$125K Sell
3,757
-26
-0.7% -$846 ﹤0.01% 1633
2014
Q3 		$111K Sell
3,783
-393
-9% -$13K ﹤0.01% 1646
2014
Q2 		$162K Buy
4,176
+141
+3% +$5.72K ﹤0.01% 1528
2014
Q1 		$169K Sell
4,035
-1,168
-22% -$48.7K ﹤0.01% 1489
2013
Q4 		$171K Buy
+5,203
New +$170K ﹤0.01% 1556

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Mason Street Advisors's LGND Position: Q1 2021 in Review

Mason Street Advisors sold out of Ligand Pharmaceuticals (LGND) in Q1 2021, closing a stake of 13,767 shares — an estimated $854K sold.

Mason Street Advisors first reported a position in LGND in Q4 2013 and held it in 29 quarters. The position peaked at $1.72M in Q3 2018. 228 funds tracked by Wall St. Rank hold LGND as of Q1 2021.

  • Mason Street Advisors reported no remaining Ligand Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Mason Street Advisors sold 13,767 Ligand Pharmaceuticals shares in Q1 2021, an estimated $854K.
  • Mason Street Advisors first reported a position in Ligand Pharmaceuticals in Q4 2013 and held it in 29 quarters.
  • Mason Street Advisors's Ligand Pharmaceuticals position peaked at $1.72M in Q3 2018.
  • 228 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2021.

Based on Mason Street Advisors's 13F filing for Q1 2021, filed 14 May 2021.